BioSpace News Archive

Aside from its manufacturing and distribution footprint, ITM Isotope Technologies Munich will give Telix Pharmaceuticals the late-stage ITM-11, being developed for gastroenteropancreatic neuroendocrine tumors. The asset was rejected by the FDA last month for manufacturing concerns.

· New U.S. subsidiary, NovAccel Isotopes Inc., established to support North American growth and long-term global supply ambitions in Ac-225 · Arnaud Lesegretain appointed Director and Chief Commercial and Business Officer of NovAccel, Inc., and CEO of NovAccel Isotopes Inc.; Takashi Mizukami appointed Director and Chief Strategy Officer